Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PYGM | P11217 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6674416 | 1.00 | CDA (0.47) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL20356797 | 0.87 | CDA (0.50) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL19590180 | 0.87 | PYGM (0.35) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6424353 | 0.86 | CDA (0.45) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17929404 | 0.80 | CDA (0.34) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23750588 | 0.78 | ALDH1A1 (0.42) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL24092278 | 0.76 | MEN1 (0.37) | MAPTLMNA | |
| SCHEMBL3498860 | 0.75 | CDA (0.67) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23240639 | 0.75 | CDA (0.67) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL8600538 | 0.75 | CDA (0.47) | CDASLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683320-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190085011-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683320-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C2 | CDA 34/4885SLC28A1 25/4885SLC28A2 29/4885 |
| US-20190085011-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | CDA 34/4885SLC28A1 25/4885SLC28A2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.